Cancer of Unknown Primary
NCI Definition: The spread of a malignant neoplasm from an unknown primary to another region remote from the primary site. 
Cancer of unknown primarys most frequently harbor alterations in TP53, KRAS, CDKN2A, KMT2D, and ARID1A .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, KRAS Mutation, and KRAS Exon 2 Mutation are the most common alterations in cancer of unknown primary .
There is 1 clinical trial for cancer of unknown primary, of which 1 is open and 0 are completed or closed. Of the trial that contains cancer of unknown primary as an inclusion criterion, 1 is phase 2 (1 open).
Nilotinib and paclitaxel are the most common interventions in cancer of unknown primary clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.